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Abstract
Background: Evaluation of renal replacement therapy with haemodialysis is essential for its improvement.
Remarkably, outcomes vary across centres. In addition, the methods used have important epistemological
limitations, such as ignoring significant features (e.g., quality of life) or no relevance given to the patient’s
perspective in the indicator’s selection. The present study aimed to determine the opinions and preferences of
stakeholders (patients, clinicians, and managers) and establish their relative importance, considering the complexity
of their interactions, to facilitate a comprehensive evaluation of haemodialysis centres.
Methods: Successive working groups (WGs) were established using a multicriteria methodology. WG1 created a
draft of criteria and sub-criteria, WG2 agreed, using a qualitative structured analysis with pre-established criteria, and
WG3 was composed of three face-to-face subgroups (WG3-A, WG3-B, and WG3-C) that weighted them using two
methodologies: weighted sum (WS) and analytic hierarchy process (AHP). Subsequently, they determined a
preference for the WS or AHP results. Finally, via the Internet, WG4 weighted the criteria and sub-criteria by the
method preferred by WG3, and WG5 analysed the results.
Results: WG1 and WG2 identified and agreed on the following evaluation criteria: evidence-based variables
(EBVs), annual morbidity, annual mortality, patient-reported outcome measures (PROMs), and patient-reported
experience measures (PREMs). The EBVs consisted of five sub-criteria: type of vascular access, dialysis dose,
haemoglobin concentration, ratio of catheter bacteraemia, and bone mineral disease. The patients rated the
PROMs with greater weight than the other stakeholders in both face-to-face WG3 (WS and AHP) and WG4 via
the Internet. The type of vascular access was the most valued sub-criterion. A performance matrix of each
criterion and sub-criterion is presented as a reference for assessing the results based on the preferences of
the stakeholders.
Conclusions: The use of a multicriteria methodology allows the relative importance of the indicators to be
determined, reflecting the values of the different stakeholders. In a performance matrix, the inclusion of
values and intangible aspects in the evaluation could help in making clinical and organizational decisions.
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Background
Since the development of dialysis in the 1960s, the treat-
ment of end-stage renal disease with dialysis has been a
challenge worldwide. Less than 0.015% of the population
is estimated to be on dialysis, but consumes approximately
2% of healthcare expenditure [1]. In Europe alone, more
than 180,000 people are undergoing renal replacement
therapy with haemodialysis in more than 4000 centres.
The estimated cost of such treatment is between 30,000
and 47,000 euros per patient per year [2, 3].
Importantly, the results of treatment with haemodialy-
sis vary between centres in both the USA and Europe.
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) detected between the different facilities of the
USA a variability in the adjusted mortality of almost
double (88.7%), in the transfusions performed of more
than double (113.9%), and in the prevalence of autolo-
gous fistulas of more than 50% (56.0%) [4]. Significant
differences were also detected among seven European
countries with regards to compliance with clinical guide-
lines [5].
On the other hand, assessment of dialysis outcomes is
generally based on partial methodologies that exclude
relevant features (e.g., quality of life, satisfaction, or
costs) or present biases (e.g., they do not consider the
perspective of the stakeholders, such as patients and
managers) [6, 7]. A substantial epistemological limitation
of evidence-based medicine has been suggested to be
that its indicators reflect the preferences of researchers,
ignoring those of other stakeholders [8]. The methods
for evaluating health outcomes should consider aspects
associated with the individuals involved, such as priori-
tizing patient-centred care, procuring their welfare, in-
corporating stakeholder participation in the evaluation,
security, transparency, and dignity, respect, and compas-
sion [9–12].
In addition, health organizations are characterized by a
large number of dynamic components that, in the real
world, interact in complex ways through frequently un-
predictable relationships. The evaluation of clinical re-
sults from a traditional perspective that ignores these
complex relationships is insufficient [13]. In this sense, it
is necessary to develop new evaluation methodology that
is more realistic and effective, and that considers the
complexity of health organizations.
Multicriteria decision analysis (MCDA), also known as
the multicriteria decision, includes a set of approaches
capable of improving decision-making in complex sys-
tems and has been recommended by the International
Society for Pharmacoeconomics and Outcomes Re-
search, Health Science Policy Council. Multicriteria
methods allow the values and preferences of the stake-
holders to be captured, integrating their different per-
spectives, adding the information in a single expression
value, and doing it transparently, consistently, and legit-
imately [14–18].
The present study aimed to determine the opinions
and preferences of the stakeholders in the treatment
with haemodialysis, to determine indicators of their re-
sults, and to establish their relative importance following
a multicriteria approach. This knowledge would allow
the creation of an instrument based on values, effectively
enabling assessment of the results of different centres,
their comparison, and then using it to improve them.
Methods
For the multicriteria study of stakeholder preferences,
five working groups (WGs) were created consecutively,
each with specific objectives. All of them were face-to-
face, except for WG4, which was via the Internet.
WG1 defined the general objectives, identified the
groups of “stakeholders” or relevant actors that provide
the preferences, and created a draft of criteria and sub-
criteria. WG2 evaluated and agreed on the criteria and
sub-criteria. WG3 was comprised of three subgroups:
WG3-A, WG3-B, and WG3-C. Each of these groups
independently, in parallel, and face-to-face weighted the
criteria and sub-criteria according to their preferences
using two different multicriteria methodologies:
weighted sum (WS) and analytic hierarchy process
(AHP). Two weeks after this weighting, a survey was
sent by email to each individual regarding their prefer-
ence for the results of the WS or AHP method. Via the
Internet, WG4 weighted the criteria and sub-criteria
only by the method with the highest preference in the
survey. In this way, a new weighting of the criteria and
sub-criteria was established through similar method-
ology, but with a larger sample in order to validate the
results of the face-to-face WG3 (obtained with a small
sample size) and guaranteeing significant conclusions.
Finally, WG5 consisted of two independent academics,
specialists in multicriteria, who analysed the results
(Fig. 1).
Working group 1
WG1 consisted of six researchers: four were nephrolo-
gists and two multicriteria analysts. The group defined
the general objective of the study and the structure and
composition of the remaining groups. The general ob-
jective was to determine the relevant criteria and sub-
criteria of haemodialysis treatment and their weighting
according to the preferences of the stakeholders. The
preferences of the stakeholders allow a “performance
matrix” summarizing the measured preferences for each
relevant criteria to be established and determine an “ag-
gregation function” that allows weights to be combined
consistently with stakeholders’ preferences. This func-
tion enables analysis of the results of the centres
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considered in the study, and establishes their individual
qualification in an orderly and justified manner.
WG1 defined the requirements and number of actors
that comprised WG2, WG3, and WG4, which included
patients, clinicians, and managers. All participants were
recruited on a voluntary basis. The patients should have
been in haemodialysis at least three years and have exer-
cised coordination tasks in some organization of kidney
patients. They were recruited from such organizations,
mainly ALCER (Asociación para la Lucha Contra las
Enfermedades Renales). The clinicians had to be of rec-
ognized prestige and extensive experience, one of them a
nephrologist, an internist, and a nurse. For the man-
agers, three profiles were defined that should be present
in each group: economic direction, medical direction,
and health services researcher. Clinicians and managers
were recruited mainly from the centres involved in the
study, they were contacted via phone-call, e-mail or per-
sonal approach. WG2 and WG3 (WG3-A, WG3-B, and
WG3-C) were each comprised of nine interested individ-
uals: three patients, three clinicians, and three managers
(total 36 individuals: 4 groups × 9 interested in each).
WG3-A was located in Alicante, WG3-B in Segovia, and
WG3-C in Zaragoza. WG4 was comprised of at least 15
stakeholders from each category (patients, clinicians, and
managers) who were located in different parts of Spain
and participated online.
The criteria and sub-criteria were identified sequentially
in two steps. First, WG1 agreed on the draft criteria, and
then WG2 agreed on the criteria. The criteria are the rele-
vant factors for the evaluation and ordering of the differ-
ent options (haemodialysis centres). These must meet
certain requirements in relation to the MCDA method-
ology used (completeness, non-redundancy, non-overlap,
and preference independence). The following principles
were also considered for the selection of draft criteria:
feasibility of its implementation, potential modifiability of
the indicator, and impact on the patient.
WG1 defined the search strategy in PubMed/Medline,
EMBASE, and Cochrane Library. The terms included
were: haemodialysis, outcomes, registry, patient reported
outcomes (and equivalents), and clinical guideline.
Fig. 1 The figure shows the working groups, their composition, flows, methodologies and objectives
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Priority was given to the PRISMA clinical guidelines
(Preferred Reporting Items for Systematic Reviews and
Meta-analyses). Two WG1 members independently
reviewed the literature results and proposed a first draft
of the criteria and sub-criteria to the rest of the group.
After a discussion in the whole group, the draft criteria
and sub-criteria were approved. An “evidence-based” cri-
terion composed of various sub-criteria was established.
To determine this, the group decided to consider only
the recommendations of level 1 in international clinical
guidelines to provide the study with transparency and
reproducibility. This decision was made in a manner
consistent with the GRADE (Grading of Recommenda-
tions Assessment, Development, and Evaluation) consid-
erations. We focus on three clinical guidelines that
provide an appropriate framework for the study: Kidney
Disease Improving Global Outcomes (KDIGO, https://
kdigo.org), European Renal Best Practice (ERBP, http://
www.european-renal-best-practice.org) and Kidney Dis-
ease Outcomes Quality Initiative (KDOQI, https://www.
kidney.org). Finally, the ultimate decision on the inclu-
sion of each criterion was made separately by the major-
ity of the group (at least four members of WG1).
Working group 2
WG2 consisted of stakeholders (3 patients, 3 clinicians,
and 3 managers) working face-to-face. The group used
WS methodology to reflect the criteria and sub-criteria
by carrying out a qualitative structured analysis of the
draft criteria and sub-criteria prepared by WG1. The de-
liberation was recorded and two independent analysts
from the group with four pre-established criteria (in-
ternal, external validity, reliability, and objectivity) con-
tributed to validating the selected criteria.
Working group 3
The face-to-face WG3 weighted the criteria and sub-
criteria agreed upon by WG2. WG3 consisted of three
subgroups, independent and parallel in time (WG3-A,
WG3-B, WG3-C). Following a multicriteria approach,
the following were performed sequentially: baseline
weighting using the WS methodology, a structured de-
bate, and a second weighting using two different multi-
criteria methodologies: WS and AHP. The purpose of
the weighting was to elicit the preferences of the stake-
holders for each of the criteria and the reasons for their
preferences.
The WS is an additive model in which the stakeholder
is invited to distribute 100 points proportionally to his
preferences among the set of criteria and sub-criteria
(total sum 100). For example, if stakeholder Patient 1
has to rank a group of four criteria according to his pref-
erences, distributing 100 points among them, the weight
could be 10 points for criteria 1, 60 for criteria 2, 10 for
criteria 3, and 20 for criteria 4. The stakeholder estab-
lishes the weights for each criterion simultaneously. The
AHP is a multicriteria technique in which, for each node
of the hierarchy considered, the stakeholder compares in
pairs the relative importance of the elements (criteria,
sub-criteria, or alternatives) that hang from it according
to the fundamental scale of Saaty [19]. The result in each
node is a positive reciprocal square matrix from which
the local priorities are obtained and a measure of the
decision-maker’s inconsistency when issuing their judg-
ments. The Super Decisions program was used for this
(https://www.superdecisions.com, sponsored by Creative
Decisions Foundation). The results obtained are trans-
ferred in the same way to a distribution of 100 points to
their preferences among all of the criteria and sub-
criteria (total sum 100 points). For example, in the AHP
model, if stakeholder Patient 1 weighs a group of four
criteria using a pairwise consecutive comparison (criter-
ion 1 with 2, criterion 1 with 3, criterion 1 with 4, criter-
ion 2 with 3, criterion 2 with 4, and criterion 3 with 4),
the comparison is made on a quantitative scale that re-
flects the importance of one criterion in relation to the
other. Both criteria can be ranked equally. The Super
Decisions program allows the weight of each criterion to
be found, in which the sum of all criteria is 100 (e.g., 10
points to criterion 1, 60 to criterion 2, 10 to criterion 3,
and 20 to criterion 4). In this way, the results obtained
by the WS and AHP methods are comparable. The as-
sessment of criteria requires a personal and collective re-
flective process based on the individual weighting and a
collective structured debate of the stakeholders, reason-
ing their different interests and perspectives to outline
the trade-offs between criteria.
Two weeks after the meeting of each WG3, a survey
was carried out with each participant. They were asked
which results (WS vs. AHP) better reflected their prefer-
ences (or none of them or both equally). The survey was
conducted blindly via email (the interviewee answered
ignoring the methodology, WS or AHP). Thus, the re-
searchers determined which method best expressed the
preferences of each stakeholder according to their
criteria.
Working group 4
WG4 again weighted the criteria and sub-criteria, but
only by the method (WS) that best expressed the prefer-
ences of WG3 in the survey. This new weighting was
performed to check the consistency of WG3’s results.
WG4 reproduced the multicriteria appraisal process of
WG3 via the Internet. It was composed of a minimum
of 15 patients, 15 clinicians, and 15 managers. Thus, the
method sequentially included a first baseline weighting
(WS), structured deliberation, and a second weighting
exclusively using the methodology preferred by WG3
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(WS or AHP). An ad hoc website was designed in
HTML5 with CSS, JavaScript and AJAX on the client
side, and PHP with MySQL on the server side, tools that
met the necessary requirements imposed by the method-
ology. The discussion via Internet was anonymous, but
the category of the stakeholder was shown (patient, clin-
ician, or manager).
Working group 5
Finally, WG5 integrated two independent academic
experts in MCDA, who analysed the results. The stat-
istical study was carried out using SPSS software and
consisted of the following phases: (i) analysis of face-
to-face results by stakeholder category and by meth-
odology (WS vs. AHP); and (ii) analysis of significant
differences between face-to-face and Internet results
by stakeholder category, a T-test of means and
ANOVA methods have been used for statistical ana-
lysis and significance. A Bonferroni test have been
used to prevent data from incorrectly appearing to be
statistically significant, if necessary.
Results
The bibliographic search carried out by WG1 resulted in
17 articles that met the requirements imposed by the
MCDA methodology. WG1 identified five criteria:
evidence-based variables (EBVs), morbidity, mortality,
patient reported outcome measures (PROMs), and pa-
tient reported experience measures (PREMs). PROMs
are health outcomes that capture symptoms, functional
status, and quality of life. PREMs measure aspects re-
lated to the humanity of care, such as the dignity of care
or communication with healthcare personnel [20]. In
turn, the EBV criteria included four sub-criteria: dialysis
dose, haemoglobin concentration, mineral and bone dis-
ease, and type of vascular access.
After the qualitative analysis, WG2 confirmed all of
the established criteria and sub-criteria and asked WG1
to include a new sub-criterion within the EBVs, the “ra-
tio of bacteraemia related to the catheter”. This modifi-
cation was detected independently by the two analysts in
the meeting as a need perceived by the three stakeholder
groups. This indicator was considered by all of the
groups to be an essential element in the safety of pa-
tients. WG1 included it when fulfilling all of the estab-
lished requirements. Table 1 reflects the final structure
of the approved criteria and sub-criteria and their defini-
tions. The criteria are defined positively to allow their
aggregation and the construction of a performance
matrix.
Table 2 shows the relative importance of the criteria
(from 0 to 100) and sub-criteria (from 0 to 100) expressed
by the members of WG3 in the second weighting. The ag-
gregate results of WG3 (A, B, and C) are shown by both
methodology (WS and AHP) and category of stakeholder
(patients, clinicians, and managers). The first weighting
and the results disaggregated by WG3 (A, B, and C) are
not collected to simplify the table. For patients, the criter-
ion most valued by both methodologies was PROMs (WS
28.33 and AHP 36.26) and it was superior to that of the
other stakeholders. For clinicians and managers, the most
valued criteria were PROMs and EBVs, depending on the
methodology used. Among the sub-criteria, the type of
vascular access was the most valued criterion with both
methodologies by all stakeholders. The analysis of face-to-
face results by stakeholder category and methodology
(WS vs. AHP) using ANOVA showed only minor signifi-
cant differences between stakeholders for the criteria of
morbidity and mineral and bone disease. Importantly,
ANOVA showed that the groups were not comparable
due to the small sample.
The results of the individual survey of WG3 are shown
in Table 3. The majority (61.5%) expressed a preference
Table 1 Criteria and sub-criteria established for haemodialysis treatment
Criteria Sub-criteria Definition
Evidence-based variables Recommendation level 1 in GRADE clinical guidelines
Type of vascular access % of patients with functioning autologous vascular access
Dialysis dose % of patients with Kt/v > 1.4 (adequate dose)
Haemoglobin concentration % of patients with haemoglobin of 11–13 g/dl
Ratio of bacteraemia related to the catheter % of patients without bacteraemia in the unit in a period of one year
Mineral and bone disease % of patients with calcium 8.4–10 mg/dl and phosphorus 2.5–4.5 mg/dl
Morbidity, annual % of patients without hospitalization in a period of one year
Mortality, annual % survival in a period of one year
PROMs % of the SF-36 quality of life survey (MCS and PCS)
PREMs % of DCQ satisfaction survey
PROM patient reported outcome measure, PREM patient reported experience measure, GRADE grading of recommendations assessment, development, and
evaluation, Kt/v: dialysis adequacy was calculated with the single pool Daugirdas II method, MCS Mental component summary from SF-36, PCS Physical
component summary from SF-36, DCQ quality of care in Dialysis Centre Questionnaire
Parra et al. BMC Health Services Research          (2020) 20:297 Page 5 of 11
for the WS method, and we decided to continue the in-
vestigation in WG4 with the WS method only.
Table 4 shows the weights of the criteria and sub-
criteria given by the members of WG4 disaggregated by
category of stakeholder (patients, clinicians, and man-
agers). In the Internet group (WG4), ANOVA only de-
tected small significant differences between stakeholders
for PROMs (P = 0.047). The Bonferroni test showed that
the differences detected were only between patient and
managers (P = 0.043). These data were not included in
the table for simplicity.
Table 4 also presents the results of WG3 disaggregated
in the same way. A comparison is made between both
WGs (WG3-A, B, C vs. WG4). The table shows that
there are no significant differences between the two
groups (face-to-face vs. Internet) for most of the results.
Table 2 Aggregated results of Working Group 3 (A, B, and C)
Patients Clinicians Managers Total
(n = 9) (n = 9) (n = 8) (n = 26)
Criteria Sub-criteria Methodology
EBV WS 26.11 (10.83) 26.66 (7.50) 24.37 (10.16) 25.77 (9.24)
AHP 20.31 (15.06) 24.62 (17.60) 29.50 (22.25) 24.63 (18.02)
Type of vascular access WS 25.55 (8.46) 26.67 (4.33) 28.75 (5.18) 26.92 (6.17)
AHP 41.66 (11.38) 40.42 (11.41) 31.98 (14.37) 38.25 (12.63)
Dialysis dose WS 26.11 (8.21) 20.56 (3.01) 21.87 (5.94) 22.88 (6.35)
AHP 18.63 (10.45) 21.17 (11.19) 19.75 (11.95) 19.85 (10.78)
Haemoglobin concentration WS 16.11 (4.17) 18.33 (2.50) 15.62 (4.17) 16.73 (3.73)
AHP 13.36 (6.18) 11.03 (7.57) 10.61 (7.00) 11.71 (6.78)
Ratio of bacteraemia related to the catheter WS 16.11 (8.21) 21.67 (7.50) 25.00 (3.78) 20.77 (7.57)
AHP 19.93 (11.95) 23.61 (10.91) 19.29 (20.68) 21.01 (14.40)
Mineral and bone disease WS 16.11 (6.97) 12.78 (7.12) 8.75 (3.54) 12.69 (6.67)
AHP 6.42 (3.47) 3.77 (0.99) 18.36 (14.22) 9.18 (10.05)
Morbidity, annual WS 15.56 (7.68) 18.89 (5.46) 18.37 (8.43) 17.57 (7.12)
AHP 23.06 (7.98) 13.15 (9.35) 15.72 (9.88) 17.38 (9.72)
Mortality, annual WS 12.22 (7.55) 18.89 (6.50) 20.00 (9.26) 16.92 (8.26)
AHP 13.76 (13.75) 20.51 (20.71) 20.68 (20.02) 18.23 (17.91)
PROMs WS 28.33 (5.00) 21.67 (4.33) 26.25 (7.44) 25.38 (6.15)
AHP 36.26 (16.76) 31.93 (12.45) 23.33 (13.23) 30.78 (14.75)
PREMs WS 17.78 (6.18) 13.89 (3.33) 11.00 (2.56) 14.34 (5.05)
AHP 6.61 (3.35) 9.77 (5.78) 10.75 (11.94) 8.98 (7.58)
The disaggregated results are shown by category of stakeholder (patient, clinician, and manager) and by methodology (WS and AHP). The first weight is not given
to simplify the table. Data are given as mean (SD)
EBV evidence-based variables, WS weighted sum, AHP analytic hierarchy process, PROM patient reported outcome measure, PREM patient reported experience
measure, SD standard deviation
Table 3 Result of the survey of the members of Working Group 3 (A, B, C) in which they were asked about the method that best
reflects their preferences (WS vs. AHP)
Preference Criteria Criteria Sub-criteria Sub-criteria
Stakeholder (n) Stakeholder (%) Stakeholder (n) Stakeholder (%)
WS 16 61.5 16 61.5
AHP 6 23.1 7 26.9
None 0 0.0 0 0.0
Both 1 3.8 0 0.0
No answer 3 11.5 3 11.5
Total 26 100.0 26 100.0
WS weighted sum, AHP analytic hierarchy process
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The only differences detected are in two parameters in
the category of clinicians: EBVs (dialysis dose, P = 0.045)
and PREMs (P = 0.025).
By presenting only minor differences between WG3 and
WG4 (face-to-face vs. Internet), both groups were consid-
ered comparable and their results added. After the
addition of WG3 and WG4, ANOVA was performed to
detect differences between stakeholders. The results
showed significant differences that were confirmed by the
Bonferroni test for the following criteria and groups: mor-
bidity, patients vs. managers (P = 0.045); PROMs, patients
vs. clinicians (P = 0.042) and patients vs. managers (P =
0.034); and PREMs, patients vs. managers (P = 0.023) and
clinicians vs. managers (P = 0.042). For the sub-criteria
and groups, the differences were ratio of bacteraemia, pa-
tients vs. managers (P = 0.007), and mineral and bone dis-
ease, patients vs. managers (P = 0.036; Table 5).
Finally, Table 6 includes a weighting proposal for each
criterion aimed at a hypothetical evaluation of the results
of haemodialysis centres. It also presents the mean
standard deviation of each criterion as a reference value
to conduct a sensitivity study of said evaluation. This
table has been prepared with the results from WG4.
Thus, the EBVs would have a weight of 24.24 points out
of the total 100 in the evaluation.
Discussion
Our study shows that there are different perceptions and
valuations among the different criteria for evaluating
haemodialysis. Thus, patients give greater importance to
PROMs than clinicians and managers, and this happens
with all three estimation methods used (face-to-face: WS
and AHP, and via Internet). The results corroborate a
finding that has already been revealed in previous re-
search using other methodologies [21, 22]. Mortality also
has a differentiated weighting: lower for patients and
higher for clinicians and managers. Despite these differ-
ences in assessment among the stakeholders, only re-
cently has the need to include the patient’s perspective
in a routine and explicit way been emphasized [23–26].
PROMs are a priority for patients and other stake-
holders, reflecting their preferences, and should be sys-
tematically considered in evaluation systems.
The objective of the evaluation of health services is
threefold: (i) to quantify the quality of the service pro-
vided; (ii) allow specific programs and activities aimed at
improvement to be established; and (iii) enable account-
ability and citizen control of the services provided. Due to
the transcendence of these objectives, it is an indispens-
able duty to have a comprehensive evaluative method-
ology that is valid, participatory, acceptable, and feasible.
The multicriteria methodology is a formal deliberative
discussion procedure that uses explicit criteria. The
method incorporates the perspective of the stakeholders
in determining the preferences of the process studied.
The preferences and intangible aspects are synthesized
in the criteria and their weights. The mathematical ex-
pression of the preferences constitutes the performance
matrix, with which an aggregation function of the results
can be constructed, capable of adding these in a single
expression value. The use of a performance matrix of in-
dicators, such as the one proposed in Table 6, provides a
measure of proportionality and uncertainty for each cri-
terion that reflects the values of the stakeholders. The
matrix can be useful to provide validity, legitimacy, and
transparency to an analysis of the results and to the
elaboration of clinical guidelines based on the values and
preferences of the stakeholders [27].
Health services are made up of a multitude of compo-
nents that interact with one another in a frequently unpre-
dictable way. They constitute “complex adaptive systems”
influenced by biochemical, cellular, physiological, genetic,
pathological, pharmacological, organizational, psycho-
logical, social, cultural, economic, and political aspects
that determine considerable uncertainty in the face of in-
dividual and collective decisions [13]. In addition, multiple
cognitive limitations in information processing interfere
with clinical and organizational decision making [28]. It
has been postulated that the conceptualization of the
health environment as a complex system can help in its
understanding and improvement, by banishing simplistic
paradigms of linear thinking [29]. In this context, the use
of an evaluation model endowed with a multiple, transdis-
ciplinary, and reflective perspective can constitute a tool
to help assess the results and make decisions closer to the
complexity of the real world.
The methodology allows a rational hierarchy of com-
plex elements, such as the different EBVs. In multicri-
teria deliberations, all EBVs were subordinated to the
type of vascular access, which is the most valued sub-
criterion, and this subordination was widely accepted by
the various stakeholders. The reason for this is that ad-
equate vascular access improves the results of the other
four EBVs, but this property does not happen the other
way around for any of the four variables. The capture of
nuances of a multilateral relationship between indicators
helps characterize them, and their knowledge facilitates
a judicious exercise of clinical practice.
The implications of this study on the evaluation of
centres are important. Health processes are complex sys-
tems in which no individual actor is knowledgeable
about the whole of their operation. Therefore, it is es-
sential to design evaluation procedures that consider
multiple perspectives and are based on broader societal
involvement to effectively improve our knowledge of the
process. With this study, we have determined the rele-
vant outcomes of haemodialysis, quantifying their rela-
tive importance and potential degree of uncertainty. An
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evaluation of dialysis centres using this methodology
may be more accurate and legitimate. In addition, this
evaluation methodology can be reproduced and used in
other homogeneous clinical processes, such as kidney
transplant, hip replacement, or many others. To enable
meaningful comparisons across centres, the case-mix
variables of those centres need to be appropriately
adjusted.
This evaluation, which considers the complexity of
health organizations, may be an effective tool in helping
clinical and management decision-making.
The study has several limitations. First, although there
is an epistemological basis for the knowledge generated,
the performance matrix could create a different struc-
ture in another cultural environment. As has been sug-
gested, the subject is rooted in a social order that is a
source of subjectivism [13]. It would be important to
validate the weighting of the criteria in a different cul-
tural environment before their practical application in it.
Second, although the concept of PREMs is defined, there
is no consensus about the use of questionnaires in prac-
tice in haemodialysis [25]. For this reason, the reflection
of the group is adequate from a conceptual perspective,
but imprecise when going down into the detail of the
content of the questionnaires due to their heterogeneity.
Despite the limitations of the study, we think that an
evaluative approach that considers these indicator
weights is more consistent than a perspective that does
not discriminate between indicators, as it better reflects
the values of the stakeholders.
Conclusions
Our results suggest that the different types of stake-
holders manifest distinct preferences among indicators,
and this happens consistently when captured by different
methodologies. Thus, patients have a greater preference
for indicators related to PROMs than clinicians and
managers, and this consideration must be incorporated
into the assessment of health services. The use of a mul-
ticriteria methodology endowed with a multifocal, trans-
disciplinary, and reflective perspective allows us to
determine the relative importance and uncertainty of the
various evaluation indicators, as a reflection of the values
of the stakeholders and society. The inclusion of values
in the evaluation, through a performance matrix, could
help with clinical and organizational decision-making in
a complex system.
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